Subtopic Deep Dive
HIV Treatment Adherence
Research Guide
What is HIV Treatment Adherence?
HIV Treatment Adherence is the consistent use of antiretroviral therapy (ART) by people living with HIV to achieve viral suppression and prevent transmission.
Research examines behavioral, psychosocial, and pharmacological barriers to ART adherence, including stigma, psychiatric disorders, and side effects. Key studies show adherence correlates with detectable drug levels and care engagement (Gardner et al., 2011, 1901 citations). Over 10 papers from 1998-2015 highlight adherence's role in treatment success, with low adherence linked to HIV acquisition in PrEP trials (Marrazzo et al., 2015, 1274 citations).
Why It Matters
Poor adherence leads to viral rebound, drug resistance, and increased transmission, undermining lifelong ART efficacy (Cohen et al., 2011). In PrEP contexts, adherence directly predicts protection, as seen in trials where low adherence nullified benefits for women (Marrazzo et al., 2015). Psychiatric disorders exacerbate non-adherence, affecting 20-50% of HIV patients and requiring integrated care (Bing et al., 2001). Stigma mechanisms hinder retention, with interventions targeting self-stigma improving outcomes (Earnshaw & Chaudoir, 2009). Engagement across the HIV care continuum—from diagnosis to adherence—supports test-and-treat strategies (Gardner et al., 2011).
Key Research Challenges
Measuring Adherence Accurately
Self-reports overestimate adherence compared to pharmacological measures like drug levels. Trials show detectable blood levels strongly predict PrEP efficacy (Grant et al., 2010). Validated tools are needed for real-time monitoring (Gardner et al., 2011).
Addressing Psychosocial Barriers
Stigma and psychiatric disorders reduce adherence, with HIV stigma mechanisms varying by context. Psychiatric issues co-occur in many patients, complicating care (Bing et al., 2001). Interventions must target enacted, anticipated, and internalized stigma (Earnshaw & Chaudoir, 2009).
Improving PrEP Adherence in Women
Adherence to tenofovir-based PrEP was low among African women, leading to no HIV prevention benefit. Intention-to-treat analyses failed due to poor pill-taking (Marrazzo et al., 2015). Long-term safety and tailored strategies remain unresolved.
Essential Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen, Ying Qing Chen, Marybeth McCauley et al. · 2011 · New England Journal of Medicine · 6.9K citations
The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by t...
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
· 1998 · Annals of Internal Medicine · 5.2K citations
Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected PersonsJune 15, 1998Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults...
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant, Javier R. Lama, Peter L. Anderson et al. · 2010 · New England Journal of Medicine · 5.0K citations
Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Insti...
Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana
Michael C. Thigpen, Poloko Kebaabetswe, Lynn Paxton et al. · 2012 · New England Journal of Medicine · 2.0K citations
Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults. The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral density, remains un...
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
Edward M. Gardner, Margaret Mclees, John F. Steiner et al. · 2011 · Clinical Infectious Diseases · 1.9K citations
For individuals with human immunodeficiency virus (HIV) infection to fully benefit from potent combination antiretroviral therapy, they need to know that they are HIV infected, be engaged in regula...
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Jean‐Michel Molina, Catherine Capitant, Bruno Spire et al. · 2015 · New England Journal of Medicine · 1.6K citations
The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal a...
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne Marrazzo, Gita Ramjee, Barbra A. Richardson et al. · 2015 · New England Journal of Medicine · 1.3K citations
None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOIC...
Reading Guide
Foundational Papers
Start with Gardner et al. (2011) for the HIV care continuum emphasizing adherence; Cohen et al. (2011) for early ART benefits; Grant et al. (2010) for PrEP adherence lessons.
Recent Advances
Marrazzo et al. (2015) on women's PrEP failures due to adherence; Molina et al. (2015) on on-demand PrEP success; TEMPRANO Group (2015) for early ART in Africa.
Core Methods
Care continuum cascade analysis (Gardner et al., 2011); pharmacological monitoring via blood levels (Grant et al., 2010); stigma mechanism scales (Earnshaw & Chaudoir, 2009).
How PapersFlow Helps You Research HIV Treatment Adherence
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map adherence literature from Gardner et al. (2011), revealing 1901 citations linking care engagement to ART adherence. exaSearch uncovers psychosocial factors in Bing et al. (2001), while findSimilarPapers extends to stigma measures from Earnshaw & Chaudoir (2009).
Analyze & Verify
Analysis Agent employs readPaperContent on Marrazzo et al. (2015) to extract adherence rates, then verifyResponse with CoVe checks claims against pharmacological data. runPythonAnalysis computes adherence-efficacy correlations from trial datasets using pandas, with GRADE grading evidence from Cohen et al. (2011) as high-quality for transmission prevention.
Synthesize & Write
Synthesis Agent detects gaps in PrEP adherence for women (Marrazzo et al., 2015) and flags contradictions between self-reports and drug levels (Grant et al., 2010). Writing Agent uses latexEditText, latexSyncCitations for Gardner et al. (2011), and latexCompile to produce manuscripts; exportMermaid visualizes care continuum cascades.
Use Cases
"Analyze adherence rates and viral suppression correlations from HIV care engagement studies."
Research Agent → searchPapers('HIV adherence viral suppression') → Analysis Agent → runPythonAnalysis(pandas on extracted trial data from Gardner et al. 2011) → statistical outputs with correlation plots and p-values.
"Draft a review on psychosocial barriers to ART adherence with citations."
Synthesis Agent → gap detection on Bing et al. 2001 and Earnshaw 2009 → Writing Agent → latexEditText + latexSyncCitations + latexCompile → LaTeX PDF with formatted bibliography and sections.
"Find code for modeling HIV adherence prediction from papers."
Research Agent → paperExtractUrls on adherence papers → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for logistic regression on stigma-adherence data.
Automated Workflows
Deep Research workflow conducts systematic reviews of 50+ adherence papers, chaining searchPapers → citationGraph → GRADE grading for structured reports on PrEP failures (Marrazzo et al., 2015). DeepScan applies 7-step analysis with CoVe checkpoints to verify stigma impacts from Earnshaw & Chaudoir (2009). Theorizer generates hypotheses on integrated psychiatric interventions from Bing et al. (2001) literature.
Frequently Asked Questions
What defines HIV treatment adherence?
Consistent daily intake of ART to maintain viral suppression below detectable levels, as required for preventing resistance and transmission (Gardner et al., 2011).
What methods measure adherence?
Pharmacological assays for drug levels outperform self-reports; detectable tenofovir levels correlated with PrEP protection (Grant et al., 2010; Marrazzo et al., 2015).
What are key papers on adherence?
Gardner et al. (2011, 1901 citations) maps the HIV care continuum; Bing et al. (2001, 1257 citations) links psychiatric disorders to non-adherence; Cohen et al. (2011, 6875 citations) shows early ART benefits with adherence.
What open problems exist?
Low PrEP adherence in women despite efficacy in men (Marrazzo et al., 2015); scalable interventions for stigma and psychiatric barriers (Earnshaw & Chaudoir, 2009; Bing et al., 2001).
Research HIV/AIDS Research and Interventions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV Treatment Adherence with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers